Wei Du1,2,3, Chen Chen1,2,4, Lin-Feng Luo1,2,3, Li-Na He1,2,3, Yixing Wang1,2,3, Xuanye Zhang1,2,3, Yixin Zhou1,2,5, Zuan Lin1,2,6, Shaodong Hong7,8,9. 1. State Key Laboratory of Oncology in South China, Guangzhou, China. 2. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 3. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 4. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 5. Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, China. 6. Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China. 7. State Key Laboratory of Oncology in South China, Guangzhou, China. hongshd@sysucc.org.cn. 8. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. hongshd@sysucc.org.cn. 9. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. hongshd@sysucc.org.cn.
Abstract
PURPOSE: The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve current treatment regimens. METHODS: The baseline and post-treatment SLD of target lesion was recorded and the maximum percent change of the SLD from baseline was designated as SLD-change score. The optimal cut-off value was obtained using the X-tile program. The relationship between SLD-change score and survival outcome (PFS, OS) was evaluated. RESULTS: 10% cut-off value of SLD-change score was found to be most distinctive for PFS. Responders defined according to this cut-off value showed a significant improvement for PFS and OS. Bone metastasis and brain metastasis were also two independent prognostic factors of PFS and OS, respectively. CONCLUSIONS: 10% SLD change score could discriminate for ICIs treatment response, which holds great promise in promoting the development of precise immunotherapeutic strategy.
PURPOSE: The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve current treatment regimens. METHODS: The baseline and post-treatment SLD of target lesion was recorded and the maximum percent change of the SLD from baseline was designated as SLD-change score. The optimal cut-off value was obtained using the X-tile program. The relationship between SLD-change score and survival outcome (PFS, OS) was evaluated. RESULTS: 10% cut-off value of SLD-change score was found to be most distinctive for PFS. Responders defined according to this cut-off value showed a significant improvement for PFS and OS. Bone metastasis and brain metastasis were also two independent prognostic factors of PFS and OS, respectively. CONCLUSIONS: 10% SLD change score could discriminate for ICIs treatment response, which holds great promise in promoting the development of precise immunotherapeutic strategy.
Authors: Katherine M Krajewski; Yoko Franchetti; Mizuki Nishino; André P Fay; Nikhil Ramaiya; Annick D Van den Abbeele; Toni K Choueiri Journal: Oncologist Date: 2014-04-22
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Fan Luo; Zhonghan Zhang; Kunlun Liao; Yang Zhang; Yuxiang Ma; Zhihuang Hu; Kangmei Zeng; Yan Huang; Li Zhang; Hongyun Zhao Journal: Ann Transl Med Date: 2019-06
Authors: John V Heymach; Boris Sepesi; Tina Cascone; William N William; Annikka Weissferdt; Cheuk H Leung; Heather Y Lin; Apar Pataer; Myrna C B Godoy; Brett W Carter; Lorenzo Federico; Alexandre Reuben; Md Abdul Wadud Khan; Hitoshi Dejima; Alejandro Francisco-Cruz; Edwin R Parra; Luisa M Solis; Junya Fujimoto; Hai T Tran; Neda Kalhor; Frank V Fossella; Frank E Mott; Anne S Tsao; George Blumenschein; Xiuning Le; Jianjun Zhang; Ferdinandos Skoulidis; Jonathan M Kurie; Mehmet Altan; Charles Lu; Bonnie S Glisson; Lauren Averett Byers; Yasir Y Elamin; Reza J Mehran; David C Rice; Garrett L Walsh; Wayne L Hofstetter; Jack A Roth; Mara B Antonoff; Humam Kadara; Cara Haymaker; Chantale Bernatchez; Nadim J Ajami; Robert R Jenq; Padmanee Sharma; James P Allison; Andrew Futreal; Jennifer A Wargo; Ignacio I Wistuba; Stephen G Swisher; J Jack Lee; Don L Gibbons; Ara A Vaporciyan Journal: Nat Med Date: 2021-02-18 Impact factor: 53.440
Authors: Andrew Rowland; Michael J Sorich; Ashley M Hopkins; Ganessan Kichenadasse; Chris S Karapetis Journal: J Immunother Cancer Date: 2020-06 Impact factor: 13.751